A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis.

Journal of oral science

Volumn 51, Issue 4, 2009, Pages 565-572

  Jham, Bruno C ^a   Chen, Haiyan ^a   Carvalho, Andre L ^a   Freire, Addah R ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETHANECHOL; MUSCARINIC AGENT; SALIVA SUBSTITUTE;

ADULT; AGED; AGEUSIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEAD AND NECK TUMOR; HUMAN; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SKULL IRRADIATION; STOMATITIS; THRUSH;

ADULT; AGED; AGEUSIA; BETHANECHOL; CANDIDIASIS, ORAL; CRANIAL IRRADIATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUCOSITIS; MUSCARINIC AGONISTS; PROSPECTIVE STUDIES; SALIVA, ARTIFICIAL; STOMATITIS;

EID: 77949704568     PISSN: None     EISSN: 18804926     Source Type: Journal    
DOI: 10.2334/josnusd.51.565     Document Type: Article

References (0)